Table 1.
Molecular detection during treatment of the patient in the study
| Detection time | Samples | Methods | Mutation (abundance %) |
|---|---|---|---|
|
03/2015 First diagnosis |
Blood | ARMS‐PCR | EGFR 19 del |
| Tumor tissue | IHC | ALK (−) | |
|
12/2016 Gefitinib resistance |
Blood | dd‐PCR | EGFR T790M (−) |
|
10/2017 Osimertinib resistance |
Tumor tissue | NGS | EGFR 19 del (16.69%); ALK rearrangement (22.29%); CDK4 amplification (CN = 16.67); NOTCH1 missense mutation (12.88%) |
| Blood | NGS | NA | |
|
07/2018 Osimertinib + crizotinib resistance |
Tumor tissue | NGS | EGFR 19 del (15.85%); ALK rearrangement (27.79%); VEGFA amplification (CN = 3.95); CDK4 amplification (CN = 12.94) |
| Blood | NGS | NA | |
|
05/2019 Post pemetrexed + bevacizumab treatment |
Blood | NGS | NA |